Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-05-09 |
Sanofi (France) Exscientia (UK) |
|
|
research - R&D - licensing |
Metabolic diseases |
Research agreement |
2017-05-09 |
Alnylam Therapeutics (USA - MA) |
|
|
nomination |
|
Nomination |
2017-05-09 |
Takeda Pharmaceutical (Japan) GammaDelta Therapeutics (UK) |
gamma delta (??) T cell therapies |
cancers including solid tumors, autoinflammatory diseases |
development |
Cancer - Oncology - Autoimmune diseases |
Development agreement |
2017-05-09 |
Tmunity Therapeutics (USA - PA) |
chief business officer |
|
nomination |
Cancer - Oncology - Autoimmune diseases - Infectious diseases |
Nomination |
2017-05-08 |
Ipsen (France) Sanofi (France) |
five consumer healthcare products including Prontalgine® |
|
pipeline acquisition |
|
Pipeline acquisition |
2017-05-08 |
Pharmaxis (Australia) Chiesi (Italy) |
Bronchitol® (mannitol) |
cystic fibrosis |
distribution |
Rare diseases - Genetic diseases |
Distribution agreement |
2017-05-08 |
Regeneron Pharmaceuticals (USA - NY) Sillajen (Republic of Korea) |
REGN2810 in combination with Pexa-Vec (pexastimogene devacirepvec) |
renal cell carcinoma |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-05-08 |
Array BioPharma (USA - CO) Merck&Co (USA - NJ) |
binimetinib and Keytruda® (pembrolizumab) |
colorectal cancer |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-05-08 |
Inovio Pharmaceuticals (USA - PA) Regeneron Pharmaceuticals (USA - NY) |
REGN2810, INO-5401, INO-9012 |
glioblastoma |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-05-08 |
Crispr Therapeutics (Switzerland - UK) the Massachusetts Institute of Technology (MIT) (USA - MA) |
Lipid Nanoparticle (LNP) technologies |
|
licensing |
Technology - Services |
Licensing agreement |
2017-05-08 |
Audentes Therapeutics (USA - CA) |
chief scientific officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-05-05 |
Seattle Genetics (USA - WA) Immunomedics (USA - NJ) |
sacituzumab govitecan (IMMU-132) |
solid tumors |
licensing |
Cancer - Oncology |
Termination of an agreement |
2017-05-05 |
Lundbeck (Denmark) |
|
|
restructuring |
|
Restructuring |
2017-05-05 |
MDxHealth (Belgium) GROW - the School for Oncology and Developmental Biology at the Maastricht University Medical Centre (The Netherlands) |
(epi)genetic-based assays |
|
research - R&D |
Cancer - Oncology |
Research agreement |
2017-05-04 |
Karo Bio (Sweden) - Pfizer (USA - NY) |
novel small molecule RORgamma modulators for the treatment of autoimmune diseases |
autoimmune diseases |
R&D |
Autoimmune diseases |
Milestone |
2017-05-04 |
Epizyme (USA - MA) GSK (UK) |
novel small molecule therapeutics targeting histone methyltransferases including GSK3326595 |
|
R&D - commercialisation |
Cancer - Oncology |
Milestone |
2017-05-04 |
Swedish Orphan Biovitrum - SOBI (Sweden) |
president and chief executive officer |
|
nomination |
Rare diseases - Genetic diseases - Hematological diseases |
Nomination |
2017-05-04 |
Crispr Therapeutics (Switzerland - UK) |
president and chief executive officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-05-03 |
Servier (France) Miragen Therapeutics (USA -CO) |
three drug candidates, including two of miRagen’s lead programs (miR-208 and miR-15/195), one additional target , MicroRNA-92 and MRG-110 |
cardiovascular diseases |
R&D
commercialisation |
Cardiovascular diseases |
R&D agreement |
2017-05-03 |
AstraZeneca (UK) Pieris Pharmaceuticals (Germany) |
Anticalin® platform, including PRS-060 |
asthma |
development - commercialisation |
Allergic diseases – Inflammatory diseases – Respiratory diseases |
Development agreement |